Haizheng Pharmaceutical Co., Ltd. applied for clinical application of class 3.1 chemical drug API for sirolimus and was accepted

Recently, according to the website of the State Food and Drug Administration (CFDA), the 3.1 chemical raw material drug tirocimose and preparation injection tirocimose applied for clinical application by Haizheng pharmaceutical were accepted According to the data, tilsirolimus was developed by Wyeth company and approved by FDA and EU in 2007 for the treatment of metastatic renal cell carcinoma It is the first-line drug for advanced renal cell carcinoma Different from other drugs in the treatment of advanced renal cancer, ticolormis can inhibit the growth and proliferation of cells, decrease the level of vascular growth factor and prevent the development of new blood vessels In addition, the product is also effective for advanced metastatic breast cancer, mantle cell lymphoma, rheumatoid arthritis and multiple sclerosis According to CFDA, tiromos has not been listed in China The concentrated solution for injection of ticolormis, which was declared by Wyeth in 2008, has been approved by CFDA and has not yet been declared for production Apart from Haizheng pharmaceutical, no domestic enterprise has declared the product